Peter Cirino - ECARX Holdings Chief Officer
| ECXWW Stock | 0.09 0.01 9.27% |
Executive
Peter Cirino is Chief Officer of ECARX Holdings Warrants
| Age | 52 |
| Address | Building 1, Zhongteng Building, Shanghai, China, 200232 |
| Phone | 86 571 8530 6942 |
| Web | https://www.ecarxgroup.com |
ECARX Holdings Management Efficiency
The company has return on total asset (ROA) of (0.1372) % which means that it has lost $0.1372 on every $100 spent on assets. This is way below average. ECARX Holdings' management efficiency ratios could be used to measure how well ECARX Holdings manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.28 in 2025. Return On Capital Employed is likely to climb to -19.22 in 2025. At this time, ECARX Holdings' Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to climb to about 216.6 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 992.5 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jim Jacobson | NewAmsterdam Pharma | N/A | |
| Bruce Bower | Gorilla Technology Group | N/A | |
| Mayur Somaiya | NewAmsterdam Pharma | 51 | |
| Namratha Joseph | Gorilla Technology Group | N/A | |
| Marc MD | NewAmsterdam Pharma | 58 | |
| Rene Du | ECARX Holdings Class | N/A | |
| Phil Zhou | ECARX Holdings Class | N/A | |
| Andrew Winterton | ECARX Holdings Class | N/A | |
| Sudha Viswanathan | Gorilla Technology Group | N/A | |
| Sheng Cui | NewAmsterdam Pharma | N/A | |
| MBA Jones | NewAmsterdam Pharma | 60 | |
| Mohan Kumar | Gorilla Technology Group | 51 | |
| Bob Rambo | NewAmsterdam Pharma | N/A | |
| MSc MBA | NewAmsterdam Pharma | 38 | |
| Jing Zhou | ECARX Holdings Class | 46 | |
| HeeWon Choi | Gorilla Technology Group | N/A | |
| M Qureshi | Gorilla Technology Group | N/A | |
| JiannCherng Luo | Gorilla Technology Group | 51 | |
| Matthew Philippe | NewAmsterdam Pharma | N/A | |
| FengShiuh Song | Gorilla Technology Group | N/A | |
| Douglas Kling | NewAmsterdam Pharma | 52 | |
Management Performance
| Return On Asset | -0.14 |
ECARX Holdings Warrants Leadership Team
Elected by the shareholders, the ECARX Holdings' board of directors comprises two types of representatives: ECARX Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ECARX. The board's role is to monitor ECARX Holdings' management team and ensure that shareholders' interests are well served. ECARX Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ECARX Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rene Du, Head Relations | ||
| Peter Cirino, Chief Officer | ||
| Andrew Winterton, General Officer | ||
| Phil Zhou, Chief Officer | ||
| Jing Zhou, Chief Officer | ||
| Ziyu Shen, CEO Chairman |
ECARX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ECARX Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.17) % | ||||
| Operating Margin | (0.05) % | ||||
| Number Of Shares Shorted | 3.8 K | ||||
| Revenue | 4.67 B | ||||
| Gross Profit | 1.15 B | ||||
| EBITDA | (814.87 M) | ||||
| Net Income | (1.02 B) | ||||
| Total Debt | 1.81 B | ||||
| Book Value Per Share | (5.27) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ECARX Stock Analysis
When running ECARX Holdings' price analysis, check to measure ECARX Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ECARX Holdings is operating at the current time. Most of ECARX Holdings' value examination focuses on studying past and present price action to predict the probability of ECARX Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ECARX Holdings' price. Additionally, you may evaluate how the addition of ECARX Holdings to your portfolios can decrease your overall portfolio volatility.